
Cancer Monthly Horoscope for August 2025
Your personal life is full of strife when Mars moves into Libra on August 6. You might need to set boundaries with a roommate or family member. Perhaps a loved one is moving through a challenging situation and relying on you more for support. This can also be a busy time at home—maybe you're moving or changing up your living space in some way.
You might feel torn between your longterm goals and the past when Mars in Libra faces off with Saturn in Aries on August 8. You could encounter a temporary setback or receive disappointing news at work or regarding a loved one. You might also feel ready to move on from the past or set a firm boundary with a toxic boss or co-worker.
The Full Moon in Aquarius on August 9 brings your deeper feelings to the surface. You're feeling raw and opening up to loved ones. This energy can be both triggering and healing. Practically, this marks a shift in your financial situation. Maybe a contract wraps up, you're paying down some debt, or you have to rework your budget.
Fortunately, financial matters begin to clear up the following day, on August 11, when Mercury retrograde in Leo ends. Conversations about a raise that were delayed pick up once again. You might also hear back from a job you applied to or feel confident enough to ask for a raise. Luck is on your side on the same day when Venus and Jupiter, the two most fortunate planets in the sky, share a kiss—in your sign! You are the main character and can use this energy however you see fit. You're feeling grateful and excited about what comes next—whether it's regarding love, friendship, personal goals, or professional milestones. Take a risk today because the Universe is on your side.
Conversations with loved ones feel grounding and it's easy to clear the air when Mercury in Leo syncs up with Mars in Libra on August 14. You could also learn news about your work situation that brings more financial stability or boosts your confidence in your own gifts or talents. Thoughtful gifts are exchanged.
The Sun enters Virgo on August 22, and you're more focused on your mindset. The next few weeks help you shift your own limiting beliefs. New, important conversations emerge and you're also full of ideas. There's a New Moon in Virgo, on the same day, that invites you to learn something new. Maybe you start learning a new hobby or a new language. You could also book travel or learn something important about a BFF, sibling, or family member. These relationships can shift and experience renewal.
Positive financial news arrives once Venus moves into Leo on August 25. The next few weeks bring financial opportunities your way or help you get back on track with your budget. You could also invest in a new wardrobe and find yourself donating old items and thrifting new ones. First, you'll have to address power struggles and uncomfortable topics regarding finances—especially in your close relationships—when Venus in Leo faces off with Pluto in Aquarius on August 26. You might need to ask for help or set a boundary with a roommate who's been taking advantage of your generosity.
The month wraps up with supportive and surprising developments on your life path when Uranus in Gemini teams up with Neptune in Aries on August 28. You are feeling divinely guided and protected. Listen to your intuition when making decisions about your future today.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
BOSTON, July 29, 2025--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET. To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, A replay of the webcast will be archived and available following the event. About Verastem OncologyVerastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit and follow us on LinkedIn. View source version on Contacts For Investor and Media Inquiries:Julissa Viana Vice President, Corporate Communications,Investor Relations & Patient Advocacy investors@ or media@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Wall Street Journal
2 hours ago
- Wall Street Journal
Mars to Invest $2 Billion in U.S. Manufacturing Through 2026
The maker of M&M's, Skittles and Kind bars is pouring billions into factories over the next 18 months. The $2 billion is on top of $6 billion Mars has already invested over the past five years, which it said added 9,000 jobs in the U.S. Mars said that 94% of its products sold in the U.S. are now made in America. The new investment will allow Mars to scale its brands and grow businesses it acquired, such as a new facility for Nature's Bakery in Utah.
Yahoo
6 hours ago
- Yahoo
AstraZeneca beats second-quarter profit expectations
(Reuters) -AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but maintained its full-year forecast as pricing pressures and global trade risks remain challenges.